Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology
HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40
Odyssey Therapeutics: Q3 Earnings Snapshot
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44
JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.